Dec 1, 2025 Log in

其他

Guangli Biotechnology Holdings Co., Ltd. 2025 Q4 Financial Report

Citation-Grade Primary-source linked Schema.org verified NQ 53 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published Dec 1, 2025 9:00 AM ・ Updated Jun 13, 2026 11:49 PM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

Guangli Biotechnology Holdings Co., Ltd.
reported an operating revenue of 377 million NTD and a net loss after tax of 193 million NTD for Q4 2025, resulting in a basic EPS of -2.07 NTD.

Guangli Biotechnology Holdings Co., Ltd. reported an operating revenue of 377 million NTD and a net loss after tax of 193 million NTD for Q4 2025, resulting in a basic EPS of -2.07 NTD.

PRIMARY SOURCE Original source: https://openapi.twse.com.tw/financial/twse-fin-6431-2025Q4 Distributor: PR Times
Published: Dec 1, 2025

Company Code: 6431, Company Name: Guangli Biotechnology Holdings Co., Ltd., Industry: Biotechnology and Medical Industry, Year/Quarter: 2025 Q4, Basic EPS: -2.07 NTD, Operating Revenue: 377 million NTD, Net Income After Tax: -193 million NTD.

FACT BOX

Source: PR Times
Category: 其他

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　Dec 1, 2025 9:00 AM — Distributor PR Times
Collected　Apr 7, 2026 8:00 AM
AI structured & analyzed　Apr 8, 2026 12:21 AM
Desk-reviewed & published　Dec 1, 2025 9:00 AM

FAQ

What are the key facts in this article?

Guangli Biotechnology Holdings Co., Ltd. reported an operating revenue of 377 million NTD and a net loss after tax of 193 million NTD for Q4 2025, resulting in a basic EPS of -2.07 NTD.

Where is the primary source?

PR Times: https://openapi.twse.com.tw/financial/twse-fin-6431-2025Q4

When was it published?

Dec 1, 2025

Cite this article — HOW TO CITE

Washin AI News Desk“Guangli Biotechnology Holdings Co., Ltd. 2025 Q4 Financial Report”AI News by Washin Village（和心村）, Dec 1, 2025. https://aeo.idaeo.ai/ai/%E5%85%89%E9%BA%97%E7%94%9F%E6%8A%80%E6%8E%A7%E8%82%A1%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8/en/news/2026-04-11-bio-shine-technology-holdings-co-ltd-202

AI CRAWLER ACTIVITY

as of Aug 20, 2026

AI crawler visits to this article (cumulative)31 bots

Site-wide cumulative

Applebot

bot_visits_summary

2425k

last Aug 20, 2026

GPTBot

bot_visits_summary

1904k

last Aug 20, 2026

ClaudeBot

bot_visits_summary

1254k

last Aug 20, 2026

Amazonbot

bot_visits_summary

672k

last Aug 20, 2026

Bingbot

bot_visits_summary

588k

last Aug 20, 2026

Meta AI

bot_visits_summary

350k

last Aug 20, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← 光麗生技控股股份有限公司 Back to newsroom (13)

Copied